BenzingaT3·7mo ago
BBP Virtus Biotech ETF
ETF 104.94 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BBP
$104.94
—
Key stats
$104.94
- 52-Week Range
- $70.27 – $110.05
- YTD
- +31.70%
- IV Rank (30D)
- 57.14
- Straddle Price
- $7.88
- P/C Vol Ratio
- 0.00
- Open
- $101.84
- Day Range
- $101.84 – $105.12
- Volume
- 8,894
- Prev Close
- $101.24
About
Virtus Biotech ETF (BBP) ETF
No description available.
- Exchange
- ARCX
- Inception
- 2014-12-16
- Has Options
- Yes
Fund profile
holdings as of Apr 30, 2026SEC filingthrough Jul 2026flows, SEC filings
- Expense ratio
- 0.34% prospectus, filed Feb 27, 2026
- Assets
- $131M shares × price, Oct 9, 2026
- Trailing yield
- —
- Average daily volume
- $1.4M 30 sessions
- Holdings
- 63 top 10 are 25.5%
- Listed
- Dec 16, 2014 NYSE Arca
- Last fee change
- -45 bp filed Feb 27, 2026
- Tracking difference
- +17.96 pts vs index, after fees, FY 2025
Cost92
Liquidity38
Scale41
Diversification79
Moves with. Small caps over large (10% of its variance, beta 0.60); US large-cap stocks (9% of its variance, beta 0.41); Long Treasuries (6% of its variance, beta 0.60); Gold (4% of its variance, beta 0.11). These factors explain 35% of its daily moves over the last year, so most of what drives this fund is something else.
Stated objective. The Virtus Biotech ETF (formerly,Virtus LifeSci Biotech Products ETF) (the Fund ) seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index (the Underlying Index ). (from the fund's prospectus)
All 63 holdingsFlow historySimilar fundsOverlap toolAll Biotech & Health Innovation ETFs
Fund flows
through Jul 2026SEC filings- Jul 2026
- +$15M latest reported month
- Latest 3 months
- +$32M +32.6% of assets
- Latest 12 months
- +$56M +57.1% of assets
View as a table
| Month | Net flow |
|---|---|
| Jul 2026 | +$15M |
| Jun 2026 | −$162K |
| May 2026 | +$17M |
| Apr 2026 | +$4.3M |
| Mar 2026 | +$4.1M |
| Feb 2026 | +$4.1M |
| Jan 2026 | $0 |
| Dec 2025 | +$12M |
| Nov 2025 | $0 |
| Oct 2025 | $0 |
| Sep 2025 | $0 |
| Aug 2025 | $0 |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 84 months ago
Similar funds
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | 42% | 0.35% | $9.9B | +45.8% | compare |
| LABUDirexion Daily S&P Biotech Bull 3X ETF | 33% | — | $553M | +123.0% | compare |
| PBEInvesco Biotechnology & Genome ETF | 32% | 0.58% | $422M | +34.5% | compare |
| IBBiShares Biotechnology ETF | 32% | 0.44% | $10.8B | +35.9% | compare |
| FBTFirst Trust NYSE Arca Biotechnology Index Fund | 31% | 0.55% | $2.9B | +41.3% | compare |
Ranked by how much of the two portfolios is the same securities.
Look-through: what the holdings say
weights as of Apr 30, 2026SEC filing- Holdings vs fair value
- +6.8% 35% under, 33% over · 84% covered
- Price / earnings
- — 62% loss-making · 88% covered
- Price / book · sales
- 4.8 · 5.6 revenue growth +14.8%
- Above 200-day average
- 54% 38% above 50-day · by weight
- Short interest
- 13.9% of float, weighted · 6.8 days to cover
- Insider buying
- 5% of weight had net insider buying, 90 days; 53% net selling
- 13F holders
- +5.2% change in shares held by institutions, latest quarter
- Reporting earnings
- 0.0% of weight in 7 days; 0.0% in 14
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
What changed in the portfolio
Jan 30, 2026 → Apr 30, 2026| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Exit | DVAXDynavax Technologies Corp | 2.18% | — | — |
| Exit | FOLDAmicus Therapeutics Inc | 2.06% | — | — |
| Exit | DAWNDay One Biopharmaceuticals Inc | 2.03% | — | — |
0 new, 3 exited, 0 increased and 0 decreased between the fund's two latest holdings reports; turnover 11.2%. Full holdings and history
Under the hood
fiscal year to Oct 31, 2025SEC census- Authorized participants
- 1 active of 16 with agreements; top 3 did 100%
- Created · redeemed
- $2.8M · $0 over the fiscal year
- Redemptions in kind
- 0% creations 100% in kind
- Creation unit
- 50,000 shares
- Securities lending
- 13.35% of assets on loan on average; earned 9.2 bp
- Return vs index
- +17.96 pts after fees; +18.75 before; daily s.d. 0.20
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
ETF Profile
holdings as of 2026-10-31
Holdings
66
AUM
$46.5M
Provider
Nport
Inception
2014-12-16
Exchange
ARCX
Data As Of
2026-10-31
Expense Ratio
0.34%
Dividend Yield
—
Distribution
—
Asset Allocation
Top Holdings
top 50 of 66 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | DREYFUS GOVERNMENT CASH MANAGE | 4.17% | Short-term investment | US |
| IBRX | ImmunityBio Inc | 4.03% | Equity (common) | US |
| MIRM | Mirum Pharmaceuticals Inc | 2.42% | Equity (common) | US |
| MRNA | Moderna Inc | 2.28% | Equity (common) | US |
| DVAX | Dynavax Technologies Corp | 2.18% | Equity (common) | US |
| FOLD | Amicus Therapeutics Inc | 2.06% | Equity (common) | US |
| NVAX | Novavax Inc | 2.05% | Equity (common) | US |
| DAWN | Day One Biopharmaceuticals Inc | 2.03% | Equity (common) | US |
| AXSM | Axsome Therapeutics Inc | 1.89% | Equity (common) | US |
| ARDX | Ardelyx Inc | 1.89% | Equity (common) | US |
| BNTX | BioNTech SE | 1.83% | Equity (common) | DE |
| GILD | GILEAD SCIENCES INC | 1.80% | Equity (common) | US |
| IOVA | Iovance Biotherapeutics Inc | 1.77% | Equity (common) | US |
| HALO | HALOZYME THERAPEUTICS INC | 1.76% | Equity (common) | US |
| KRYS | Krystal Biotech Inc | 1.74% | Equity (common) | US |
| AMGN | Amgen Inc | 1.64% | Equity (common) | US |
| ONC | BeOne Medicines Ltd | 1.62% | Equity (common) | US |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 1.62% | Equity (common) | US |
| — | Kiniksa Pharmaceuticals Intern | 1.61% | Equity (common) | US |
| INCY | INCYTE CORP | 1.60% | Equity (common) | US |
| — | THERAVANCE BIOPHARMA INC | 1.59% | Equity (common) | KY |
| VRTX | VERTEX PHARMACEUTICALS INC | 1.58% | Equity (common) | US |
| BIIB | BIOGEN INC | 1.57% | Equity (common) | US |
| BBIO | Bridgebio Pharma Inc | 1.57% | Equity (common) | US |
| ASND | Ascendis Pharma A/S | 1.56% | Equity (common) | DK |
| IONS | IONIS PHARMACEUTICALS INC | 1.56% | Equity (common) | US |
| LGND | LIGAND PHARMACEUTICALS | 1.54% | Equity (common) | US |
| EXEL | EXELIXIS INC | 1.54% | Equity (common) | US |
| GERN | Geron Corp | 1.53% | Equity (common) | US |
| AGIO | AGIOS PHARMACEUTICALS INC | 1.53% | Equity (common) | US |
| REGN | REGENERON PHARMACEUTICALS | 1.52% | Equity (common) | US |
| PTCT | PTC Therapeutics Inc | 1.52% | Equity (common) | US |
| SNDX | Syndax Pharmaceuticals Inc | 1.52% | Equity (common) | US |
| CRNX | Crinetics Pharmaceuticals Inc | 1.51% | Equity (common) | US |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.51% | Equity (common) | US |
| — | Roivant Sciences Ltd | 1.49% | Equity (common) | US |
| UTHR | UNITED THERAPEUTICS CORP | 1.45% | Equity (common) | US |
| SRPT | SAREPTA THERAPEUTICS INC | 1.44% | Equity (common) | US |
| PHAT | Phathom Pharmaceuticals Inc | 1.43% | Equity (common) | US |
| TGTX | TG Therapeutics Inc | 1.43% | Equity (common) | US |
| ZLAB | Zai Lab Ltd | 1.42% | Equity (common) | CN |
| ACAD | ACADIA Pharmaceuticals Inc | 1.41% | Equity (common) | US |
| KALV | KalVista Pharmaceuticals Inc | 1.41% | Equity (common) | US |
| AUPH | Aurinia Pharmaceuticals Inc | 1.40% | Equity (common) | CA |
| RYTM | Rhythm Pharmaceuticals Inc | 1.37% | Equity (common) | US |
| HRMY | Harmony Biosciences Holdings I | 1.37% | Equity (common) | US |
| APLS | Apellis Pharmaceuticals Inc | 1.36% | Equity (common) | US |
| TVTX | Travere Therapeutics Inc | 1.36% | Equity (common) | US |
| NBIX | NEUROCRINE BIOSCIENCES INC | 1.36% | Equity (common) | US |
| IMCR | Immunocore Holdings PLC | 1.35% | Equity (common) | GB |
Geographic Breakdown
Non-Equity Breakdown
Virtus Biotech Etf ·
NPORT-P period 2026-04-30
(filed 2026-06-22)
Net assets:
$59M
· 63 total positions
· equity 99.54%
· non-equity 3.15%
Non-equity holdings
— 1 positions,
3.15% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 3.15% | $1.9M | 1 |
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 5.68% | -13.40% | 6.83% | -2.64% | 2.65% | 2.44% | 0.26% |
| Feb | -4.47% | -4.03% | -5.50% | 2.66% | 0.23% | 2.58% | -1.42% |
| Mar | -5.71% | 3.51% | -0.76% | -6.64% | -1.19% | -1.71% | -2.08% |
| Apr | 1.20% | -13.80% | 4.31% | -5.95% | 3.67% | 1.25% | -1.55% |
| May | -4.43% | -4.15% | -0.26% | 3.99% | -4.26% | 1.90% | -1.20% |
| Jun | 3.63% | 9.79% | 0.85% | 1.93% | 1.27% | 13.97% | 5.24% |
| Jul | -6.84% | -0.41% | 4.64% | 6.07% | 5.43% | -2.12% | 1.13% |
| Aug | 3.48% | 13.28% | -2.92% | 3.90% | 8.54% | 12.94% | 6.54% |
| Sep | -4.25% | -5.76% | -7.02% | 0.29% | 1.57% | -1.66% | -2.80% |
| Oct | 2.05% | 1.03% | -4.56% | 1.86% | 5.14% | 1.50%* | 1.17% |
| Nov | -9.53% | 5.52% | 7.93% | 1.95% | 8.62% | -- | 2.90% |
| Dec | 3.68% | -1.56% | 11.29% | -8.76% | 2.26% | -- | 1.38% |
| Total | -15.70% | -12.93% | 13.82% | -2.58% | 38.70% | 34.01% | 9.22% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $103.86
SMA 50: $103.87
SMA 200: $90.77
Current: $104.76
EMA 12: $103.40
EMA 26: $103.85
MACD: -0.4453 | Signal: -0.2724
BEARISH
ADX (14): 15.21
RANGE
+DI: 24.22
−DI: 25.41
Momentum Oscillators
RSI (14): 52.52
NEUTRAL
Stoch %K: 34.65
Stoch %D: 24.54
Williams %R: -38.06
Volume & Volatility
BB Upper: $107.42
BB Lower: $100.31
NEUTRAL
OBV: 471,910
Vol SMA 20: 16,112
Vol ROC: 10.91%
ATR: $2.39
True Range: $3.88
HV 20: 28.0%
HV 30: 26.2%
HV 60: 26.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-11T00:00:00 – 2026-10-09T00:00:00
AI Analysis
LLM Stock Analysis Report: BBP
Executive Summary
BULLISH/BEARISH: NEUTRAL (Confidence Level: 5)
Key Drivers:
- Bullish momentum from MACD signal line crossover
- Neutral RSI reading, indicating a consolidation phase
- Supportive volume trends and institutional interest signals
Primary Risks:
- Downtrend risk if price breaks below SMA 200 level ($85.41)
- Volatility risk due to high beta (0.81) relative to market
Investment Thesis: BBP appears to be consolidating after a recent uptrend, with bullish momentum indicators and supportive volume trends. While there are some risks to consider, the stock's moderate volatility and institutional interest suggest it may continue to trend upward in the near term.
Recent News Sentiment Impact: The neutral news sentiment from recent headlines does not appear to have had a significant impact on the stock price, which is consolidating around its current level.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Consolidation phase with an uptrend bias Medium-term (1-3 months): Uptrend (SMA 50 above SMA 20) Long-term (3-12 months): Uptrend (SMA 200 above SMA 50)
Support/Resistance Levels: Key price levels to monitor:
- SMA 20: $98.31
- SMA 50: $95.66
- SMA 200: $85.41
Momentum Signals: RSI interpretation: Neutral reading (66.84), indicating a consolidation phase. MACD signal line crossover: Bullish momentum.
Bollinger Bands position: Neutral, with price hovering near the middle band.
Volume Analysis: Volume trends are supportive of the uptrend, with institutional interest signals suggesting continued buying pressure.
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines do not appear to have had a significant impact on the stock price, which is consolidating around its current level. The neutral sentiment suggests that any potential market moves will be driven by technical or fundamental factors rather than news-driven sentiment.
Sentiment Assessment: Neutral sentiment from recent headlines does not support or contradict the technical signals.
Catalyst Identification: Upcoming catalysts to monitor:
- Earnings date: Not available
- Regulatory changes: None identified
Risk & Volatility Assessment
Beta Interpretation: Moderate volatility risk due to a beta of 0.81 relative to market.
Volatility Regime: Current volatility levels are moderate, with historical volatility ranging from 18.8% (HV20) to 23.9% (HV30).
Options Market Signals: IV rank: Low (10.3%), suggesting historically low volatility. Put/call ratios: Neutral sentiment.
Market Context & Positioning
Sector Performance: Biotech sector has been performing well recently, with BBP's moderate volatility and institutional interest suggesting it may continue to trend upward in the near term.
Institutional Activity: Volume patterns suggest continued buying pressure from institutions.
Correlation Analysis: BBP is moderately correlated (0.44) with the broader market, indicating that it tends to follow market trends but also exhibits some independent movement.
Key Levels & Action Items
Critical Price Levels: Support levels:
- SMA 20: $98.31
- SMA 50: $95.66
Resistance levels:
- SMA 200: $85.41
Breakout/Breakdown Levels:
- Break above SMA 200 for a strong uptrend signal.
Time-Sensitive Catalysts:
- Earnings date: Not available (monitor for any changes)
Risk Management: Stop-loss levels around the SMA 20 level ($98.31) and position sizing considerations to manage risk.
By analyzing the technical indicators, news headlines, and risk metrics, we can conclude that BBP is in a consolidation phase after a recent uptrend. The bullish momentum from MACD signal line crossover and supportive volume trends suggest continued upward movement in the near term. However, there are some risks to consider, such as the potential for a downtrend if price breaks below SMA 200 level or increased volatility due to high beta relative to market.
Generated
News
All BBP news →
BenzingaT3·17mo ago
GlobeNewswire Inc.T3·18mo ago
Zacks Investment ResearchT3·27mo ago
Zacks Investment ResearchT3·33mo ago
Zacks Investment ResearchT3·44mo ago
Zacks Investment ResearchT3·46mo ago
Zacks Investment ResearchT3·49mo ago
Zacks Investment ResearchT3·50mo ago
Zacks Investment ResearchT3·50mo ago
Showing 1–10 of 15
Page 1 of 2
BBP Options Activity & IV Rank
BBP IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 27.8%
7-DTE IV: 27.8%
Expected Move: $7.88
7-DTE Move: $3.25
Days to Exp: 42 (2026-11-20)
Options Flow
Call Volume: 1
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 0
Put OI: 0
P/C OI: —
Total OI: 0
ATM Options Pricing
ATM Call: $4.12
ATM Put: $3.75
Call %: 3.9%
Put %: 3.6%
Chain Summary
Chain Volume: 20
Chain OI: 20
Last Updated: 10/9/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 9 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 9 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)8.9LowOct 9
IV Rank (30 DTE)57.1MediumOct 9
Straddle Price (30 DTE)$7.88Oct 9
Beta Analysis
Risk Metrics
Beta: 0.8439
Alpha: 27.48%
Correlation: 0.4260
R-Squared: 18.1%
Stock Volatility: 25.8%
Market Volatility: 13.0%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
BBP Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
5.12K
SI % of Float
0.41%
Days to Cover
1.00
Short Vol Ratio
27.0%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-09
BBP Constituent Performance
Click any bar to view the full quote for that stock.
BBP Constituents (60 of 61)
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| IBRX | ImmunityBio Inc | 4.03% | $10.51 | +6.05% | +2.19% | +32.87% |
| MIRM | Mirum Pharmaceuticals Inc | 2.42% | $86.01 | +5.73% | +3.71% | -12.43% |
| MRNA | Moderna Inc | 2.28% | $225 | +14.21% | +18.41% | +56.28% |
| DVAX | Dynavax Technologies Corp | 2.18% | $15.5 | +0.00% | +0.06% | +0.58% |
| FOLD | Amicus Therapeutics Inc | 2.06% | $14.49 | +0.21% | +0.21% | +0.42% |
| NVAX | Novavax Inc | 2.05% | $12.75 | +15.80% | +21.89% | +35.35% |
| DAWN | Day One Biopharmaceuticals Inc | 2.03% | $21.53 | +0.19% | +0.28% | +0.70% |
| AXSM | Axsome Therapeutics Inc | 1.89% | $168.35 | -1.02% | -6.08% | -23.74% |
| ARDX | Ardelyx Inc | 1.89% | $3.28 | +0.31% | -1.80% | -8.38% |
| BNTX | BioNTech SE | 1.83% | $96.96 | +5.32% | +0.06% | +0.24% |
| GILD | GILEAD SCIENCES INC | 1.80% | $151.17 | +2.77% | +4.44% | +5.18% |
| IOVA | Iovance Biotherapeutics Inc | 1.77% | $14.62 | +9.84% | +2.85% | +70.00% |
| HALO | HALOZYME THERAPEUTICS INC | 1.76% | $110.42 | +0.53% | +0.51% | +3.00% |
| KRYS | Krystal Biotech Inc | 1.74% | $331.61 | +1.32% | +2.89% | -4.44% |
| AMGN | Amgen Inc | 1.64% | $414.87 | +1.82% | +2.94% | +9.94% |
| ONC | BeOne Medicines Ltd | 1.62% | $354.47 | +1.24% | -1.01% | +2.30% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 1.62% | $54.8 | -0.17% | -4.17% | -16.57% |
| INCY | INCYTE CORP | 1.60% | $112.79 | +0.04% | -2.18% | -7.15% |
| VRTX | VERTEX PHARMACEUTICALS INC | 1.58% | $510.08 | +1.36% | +1.06% | -1.04% |
| BIIB | BIOGEN INC | 1.57% | $225.71 | +3.33% | +2.65% | +3.94% |
| BBIO | Bridgebio Pharma Inc | 1.57% | $65.35 | +0.48% | -2.83% | -9.79% |
| ASND | Ascendis Pharma A/S | 1.56% | $229.23 | +2.94% | +0.60% | -13.01% |
| IONS | IONIS PHARMACEUTICALS INC | 1.56% | $45.28 | +4.57% | +4.00% | -16.47% |
| LGND | LIGAND PHARMACEUTICALS | 1.54% | $301.81 | +2.31% | -0.38% | +6.10% |
| EXEL | EXELIXIS INC | 1.54% | $59.86 | +1.42% | +2.52% | +6.66% |
| GERN | Geron Corp | 1.53% | $1.23 | +0.41% | +2.08% | -9.26% |
| AGIO | AGIOS PHARMACEUTICALS INC | 1.53% | $31.81 | -0.34% | +0.03% | -5.33% |
| REGN | REGENERON PHARMACEUTICALS | 1.52% | $746.54 | +0.94% | +1.54% | -4.47% |
| PTCT | PTC Therapeutics Inc | 1.52% | $64.7 | +3.42% | +1.95% | -2.06% |
| SNDX | Syndax Pharmaceuticals Inc | 1.52% | $16.99 | +0.53% | -3.47% | -6.55% |
| CRNX | Crinetics Pharmaceuticals Inc | 1.51% | $84.95 | +0.13% | +0.20% | +1.42% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.51% | $62.75 | +3.31% | -2.24% | -24.26% |
| UTHR | UNITED THERAPEUTICS CORP | 1.45% | $549.16 | +3.07% | +1.38% | +10.47% |
| SRPT | SAREPTA THERAPEUTICS INC | 1.44% | $17.85 | -1.98% | +2.00% | -12.71% |
| PHAT | Phathom Pharmaceuticals Inc | 1.43% | $7.25 | +1.68% | +4.77% | -13.28% |
| TGTX | TG Therapeutics Inc | 1.43% | $55.37 | +3.81% | +1.99% | +2.75% |
| ZLAB | Zai Lab Ltd | 1.42% | $24.99 | +0.73% | +2.71% | +3.52% |
| ACAD | ACADIA Pharmaceuticals Inc | 1.41% | $19.78 | +1.02% | -0.85% | -28.93% |
| KALV | KalVista Pharmaceuticals Inc | 1.41% | $27 | +0.04% | +0.19% | +1.01% |
| AUPH | Aurinia Pharmaceuticals Inc | 1.40% | $16.65 | +2.65% | +5.18% | +3.42% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.37% | $90.78 | +1.27% | -2.21% | -13.30% |
| HRMY | Harmony Biosciences Holdings I | 1.37% | $40.28 | +1.72% | +1.61% | -2.99% |
| APLS | Apellis Pharmaceuticals Inc | 1.36% | $41.03 | -0.07% | -0.22% | +0.45% |
| TVTX | Travere Therapeutics Inc | 1.36% | $52.12 | +0.16% | -8.44% | -21.23% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 1.36% | $142.44 | +0.84% | -0.52% | -8.82% |
| IMCR | Immunocore Holdings PLC | 1.35% | $29.39 | +1.03% | -1.08% | -9.85% |
| ESPR | Esperion Therapeutics Inc | 1.34% | $3.18 | -0.31% | +0.63% | +1.27% |
| ADMA | ADMA Biologics Inc | 1.33% | $10.36 | +0.29% | +6.58% | +12.24% |
| ARQT | Arcutis Biotherapeutics Inc | 1.33% | $26.58 | +8.53% | +5.64% | +11.28% |
| LENZ | LENZ Therapeutics Inc | 1.33% | $3.65 | +3.26% | +1.82% | -19.36% |